3 completed, 1 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow PF-05231023: new trials by email Literature Review of PF-05231023 trials Research Report on PF-05231023
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiple Dose Study Of PF-05231023 In Obese Adult Subjects Placebo, 100 mg PF-05231023 - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Terminated | Pfizer | 4 | 2013-09-01 | 2014-09-17 |
| Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus Placebo, 25 mg PF-05231023, 50 mg PF-05231023 - Diabetes Melliuts, Type 2 | Phase 1 | Completed | Pfizer | 107 | 2012-10-01 | 2015-02-16 |
| Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes PF-05231023, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Pfizer | 50 | 2011-07-01 | 2015-01-12 |
| Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes PF-05231023, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Pfizer | 84 | 2011-02-01 | 2016-11-18 |
Diabetes Mellitus, Type 2 (4) · Obesity (1)
Pfizer (4)
United States (4)